F+FreeMedSite USMLELearn with clinical reasoning
SEPARATE VIVA EXTENSION

SGLT2 inhibitor-associated euglycemic ketoacidosis

Follow-up oral questions and concise, clinically defensible model answers. Your MCQ remains open in its original tab.

← Return to original MCQ
EXAMINER FOLLOW-UP 1

Where is SGLT2 mainly expressed?

Early proximal convoluted renal tubule.

EXAMINER FOLLOW-UP 2

What is the dominant renal effect of an SGLT2 inhibitor?

Increased urinary glucose excretion.

EXAMINER FOLLOW-UP 3

What tests confirm suspected euglycemic DKA?

Blood beta-hydroxybutyrate with serum electrolytes/anion gap and venous or arterial acid-base assessment.